Shares of Hims & Hers Health Inc. (HIMS) surged 5.10% in pre-market trading on Tuesday, continuing the rebound that began in after-hours trading on Monday. This upward movement comes as investors reassess the impact of the company's recent split with Danish pharmaceutical giant Novo Nordisk.

The volatility in HIMS stock began on Monday when Novo Nordisk announced the termination of its partnership with Hims & Hers for the sale of weight loss drugs, including the popular Wegovy. Novo Nordisk cited concerns over "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk." This news initially caused HIMS stock to plummet by approximately 35% during Monday's regular trading session.

However, Hims & Hers CEO Andrew Dudum strongly refuted these allegations, stating that Novo Nordisk was "misleading the public" and had pressured his company to "control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients." Dudum emphasized that Hims & Hers would continue to offer a range of treatment options, including Wegovy, to ensure providers can serve individual patient needs. This response, coupled with the company's commitment to maintaining a diverse treatment portfolio, appears to have reassured some investors, contributing to the stock's recovery.

The pre-market rally suggests that the market is re-evaluating the long-term impact of the partnership dissolution on Hims & Hers' business model. While the situation remains fluid, the company's ability to provide various treatment options, including compounded medications, could be viewed as a strength by some market participants. As trading opens on Tuesday, all eyes will be on HIMS to see if this positive momentum can be sustained amidst the ongoing controversy.